Thank you to our speakers, sponsors, and delegates who joined us in Boston for the 2nd Precision Medicine in Inflammatory Bowel Disease Summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com

Uniting Large Pharma, Innovative Biotech & Leading Academics Dedicated to Accelerating Precision Medicine Therapies to Patients in Need

The industry has made unequivocal advances, from tangible progress using artificial intelligence to robust biomarker development, permitting precise prognosis, astute stratification, and meticulous patient monitoring. Unsurprisingly, this is reflected by countless recent approvals, IND filings, and new companies emerging out of stealth-mode.

The Precision Medicine in Inflammatory Bowel Disease Summit returned for the second year, as the most comprehensive, ultra-specialized meeting and united experts to explore developments to fast-track the optimization of drug development and overcome the one-size-fits-all approach to medicine. 

What Was New for 2024?

AI icon

Breakthroughs from AI-driven drug repurposing to the AI-enhanced development of wearable technology to monitor IBD disease state at the brand-new AI & Machine Learning dedicated focus day

Speaker Icon

Fresh insights from a brand-new speaker faculty, including thought leaders from Bristol Myers Squibb, Takeda, Merck, Seres Therapeutics, Palatin Technologies, Alumis, and many more

Data icon

With new speakers came new data: attendees gained actionable insights on novel strategies, exciting developments and future perspectives to fast-track development in their field

2024 Expert Speakers Included:

Attending Companies Included:

40556 - Companies Attending (2)

Testimonials

This meeting presents a great opportunity to connect with others in the Precision Medicine field to share ideas and ways in which to better benefit patients

Past Attendee, Scientific Director, Precision Medicine & Immunology, AbbVie 

This meeting provides a great opportunity to strengthen the case for precision medicine in IBD which will be hugely beneficial for patients.”

MIT

2024 Partners:

Other Events In The Series